




Objective:  To determine the course of sleep distrurbance (insomnia symptoms and 
short sleep duration) after a diagnosis of epilepsy and their associations with seizure 
control, mood, disability, and quality of life. 
Patients and Methods:  One hundred and sixty-nine adults were drawn from the 
Sydney Epilepsy Incidence Study to Measure Illness Consequences (SEISMIC), a 
prospective, multicenter, community-wide study in Sydney, Australia.  Socio-
demographic, psychosocial, clinical characteristics, and information on sleep 
disturbance were obtained early (median 48 [IQR15-113] days) after a diagnosis of 
epilepsy, and at 12 months.  Logistic regression models were used to determine 
associations between patterns of sleep disturbance with outcomes at 12 months. 
Results:  Insomnia symptoms and/or short sleep duration were present in 18-23% of 
participants at both time points, with over half (54-61%) showing a chronic pattern.  
There was no association of sleep disturbance pattern with recurrent seizures, 
medication use or disability.  Chronic insomnia symptoms and short sleep duration 
were strongly associated with worse mental health (aOR 3.76, 95% CI 1.28-11.06; and 
aOR 5.41, 95% CI 1.86-15.79) and poorer quality of life at 12 months (aOR 3.02, 95% 
CI 1.03-8.84; and aOR 3.11, 95% CI 1.10-8.82), after adjusting for clinical features of 
epilepsy and comorbidity.  Those whose sleep disturbance remitted had no adverse 
outcomes. 
Conclusions:  Insomnia symptoms and short sleep duration are less common in 
people with recently-diagnosed than chronic epilepsy.  The temporal association with 










Adults with epilepsy show significantly more sleep-related disturbance than the general 
population [1].  Insomnia, defined variously, affects between one quarter and one half 
[2, 3] of adults with epilepsy, with one third sleeping six or fewer hours per night 
according to the 2010 National Health Interview Survey of USA [4].  Epilepsy can 
disrupt sleep, and some possible mechanisms include alterations in neuronal 
synchronizational activity [5] and thalamocortical/corticothalamic networks [6] and 
medication-related effects [7].  An example of this relationship is the improvement in 
subjective daytime sleepiness and sleep quality that patients with drug-resistant 
temporal lobe epilepsy experience after epilepsy surgery [8].  Conversely, sleep 
deprivation has long been recognized as lowering seizure thresholds [9], while 
improved seizure control has been noted in those who have been successfully treated 
for co-occurring sleep apnea [10].  Sleep disorders are associated with anxiety and 
depression, suicidal ideation and reduced quality of life in adults with epilepsy [11, 12]. 
Sleep problems occur early after a diagnosis of epilepsy.  Recently diagnosed patients 
display greater sleep instability and fragmentation than those whose epilepsy was 
diagnosed several years previously [13].  However, most studies of this topic have 
been cross sectional, with consequent selection and information biases, and limitations 
over causal inference.  We analyzed data from the Sydney Epilepsy Incidence Study 
to Measure Illness Consequences (SEISMIC) to determine the course of insomnia 
symptoms and short sleep duration in adults with a new diagnosis of epilepsy, and 
whether these variables were associated with seizure control, anxiety or depression, 
disability and quality of life. 
2. Patients and Methods 




SEISMIC is registered on the Australia New Zealand Clinical Trial Registration 
database, and the protocol and main results are published [14-17].  In brief, people of 
all ages with a new diagnosis of epilepsy were identified and enrolled through a 
geographically based multi-site ascertainment process in Sydney, Australia from July 
2008 to December 2013.  Epilepsy was defined as 2 or more unprovoked seizures, 
defined according to the International League Against Epilepsy (ILAE) Commission on 
Epidemiology and Prognosis as “a transient occurrence of signs or symptoms due to 
abnormal excessive or synchronous neuronal activity in the brain.”  Only adult 
participants (i.e. ≥18 years) are included in the current analyses. 
2.2 “A new diagnosis of epilepsy” case ascertainment and confirmation 
A surveillance system was established across hospitals in Sydney: Bankstown 
Hospital, Prince of Wales Hospital, Royal Prince Alfred Hospital, St. Vincent's Hospital, 
Sydney Children's Hospital at Randwick, Westmead Hospital including Westmead 
Children's Hospital, Concord Repatriation General Hospital, and Canterbury Hospital.  
This approach involved regular review of the records of all patients who presented to 
any of those hospital areas: neurology outpatient clinics and departments, EEG labs, 
Centre of the University of Sydney, referrals from private consulting rooms of 
epileptologists, neurologists, pediatricians, and general practitioners, and cases 
referred directly from Epilepsy Action Australia, a not-for-profit nongovernment 
organization, were also reviewed.  A lead clinician at each referral site, principal 
investigators, maintained a screening log of all potentially eligible patients and 
documented when consent was obtained.  Clinical information required to determine 
“a new diagnosis of epilepsy” of consented participants were abstracted from medical 





Trained research nurses then undertook in-person structured interviews with 
participants within 28 days of, or as soon as possible after, their diagnosis (baseline), 
and 12 months later.  Each interview included clinical and age-specific psychosocial 
assessments [14, 15]. 
2.4 Sleep disturbance measures 
Insomnia symptoms and short sleep duration were ascertained using the Pittsburgh 
Sleep Quality Index (PSQI) [19], which has been validated in adults with epilepsy, and 
shows similar relations to demographic and clinical characteristics as other common 
scales, such as the Insomnia Severity Index [3] and the Epworth Sleepiness Scale [8]. 
Insomnia symptoms were ascertained using two items, rated on a 4-point frequency 
scale: “During the past month, how often have you had trouble sleeping because” (1) 
“you cannot get to sleep within 30 minutes?” and (2) “you wake up in the middle of the 
night or early morning?”.  Overall sleep quality was assessed using the final question 
“During the past month, how would you rate your sleep quality overall?” rated on a 4-
point scale (“very good” to “very bad”).  The combination of responses of “three or more 
times a week” to (1) and/or (2), plus “fairly bad” or “very bad” overall sleep quality, were 
defined as “insomnia symptoms”.  An “insomnia symptoms course” variable was 
created as: (1) “chronic”, insomnia symptoms present at baseline and 12 months; (2) 
“recovery”, insomnia symptoms present at baseline but not at 12 months; (3) “late”, 
insomnia symptoms first present at 12 months; and (4) “never”, no insomnia symptoms 
at either baseline or 12 months. 
Sleep duration was ascertained from the single question “During the past month, on 
average, how many hours of actual sleep did you get at night?”.  Short sleep duration 
was defined as less than the National Sleep Foundation (NSF)’s minimum 




by Australian Sleep Health Foundation.  A “short sleep duration course” variable (i.e. 
chronic, recovery, late and never) was created as above. 
2.5 Other measures 
Information collected included demographic and socioeconomic characteristics, 
psychosocial factors, history of other physical disorders, etiology and clinical pattern of 
seizures, use of antiepileptic drugs (AEDs), and family history of epilepsy.  Participants 
whose baseline assessments were undertaken beyond the initial 28-day period, were 
asked to recall their situation within the first month of diagnosis, except for the 
information on “current” use of AEDs.  Economic hardship was defined as either a 
household’s inability to make a necessary household payment or the demonstration of 
dissaving behavior, compising 16 items from financial strain questions of the Australian 
Bureau of Statistics Household Expenditure Survey [21].  Family function was 
assessed with the Family Adaptation, Partnership, Growth, Affection and Resolve 
(APGAR) questionnaire [22].  Alcohol consumption was assessed using the World 
Health Organization’s Alcohol Use Disorders Identification Test (WHO-AUDIT-c) [14, 
23].  Perceived job stress was determined using a short form of the Job Content 
Questionnaire (JCQ) [24].  Job strain was defined as combination of high demands 
and low control.  Prior treatment for mood disorders includes history of taking 
antidepressants, sleeping tablets, medication for anxiety/anxiolytics/benzodiazepines 
or major tranquilizers and psychotherapy.  Perceived stigma was determined by a 
single question of whether the participant thought that other people were 
uncomfortable, treated him/her differently, or preferred to avoid him/her.  Co-morbidity 
included self-reported cardiovascular, respiratory, ophthalmology, otorhinolaryngology, 




metabolic diseases, but not including neurological (e.g. epilepsy) and 
psychiatric/behavioral conditions. 
2.6 Outcome measures 
Seizure control was assessed at 12 months by a single question about the 
presence/absence of seizures in the past eight months.  Anxiety and depression were 
measured using the Hospital Anxiety and Depression Scale (HADS) subscales,[25] 
which contain 7 items on a 4-point scale.  A score of ≥8 on these subscales indicates 
anxiety or depression, respectively.  Disability was measured using the 12-item World 
Health Organization`s Disability Assessment Schedule (WHODAS, 
http://www.who.int/classifications/icf/whodasii/en/), with higher scores indicating more 
disability; the measure was dichotomized at the median as high (≥2) and low (≤1) 
disability.  Quality of life was measured on the EuroQol Group 5-Dimension self-
reported questionnaire (EQ-5D), including the 11-point visual analogue scale (VAS) 
where scores of 10 and 0 indicate the “best possible” and “worst possible” (i.e. as bad 
as or worse than being dead) quality of life, respectively.  Participants, with lower than 
the median EQ-5D score (cut point at <1) or a global rating of quality of life (≤7), were 
categorized as the group with poorer quality of life. 
2.7 Analysis 
We assessed the potential for selection bias by comparing those with and without full 
sleep or follow-up data, and for information bias by comparing the samples according 
to time of baseline assessment (≤ versus >28 days).  In complete-case analyses, 
Kruskal-Wallis and chi-squared tests were used to estimate associations of baseline 





The point frequency at baseline and 12 months, and the pattern of insomnia symptoms 
and short sleep duration over these two assessments, were calculated.  The insomnia 
symptoms or short sleep duration course variable was used as the “exposure” in the 
models.  Logistic regression models were used to determine associations of the course, 
with 12 months outcomes: presence/absence of seizures in the past eight months, 
presence/absence of anxiety or depression, disability, and quality of life.  Models were 
first adjusted for age (continuous) and sex (model I), then sequentially for on/off 
antiepileptic medication at 12 months, and presence/absence of ongoing seizures in 
the past 8 months at 12 months assessment (not applicable for the outcome of seizure 
control) (model II); and then sequentially for history of treatment for mood disorders 
before the first seizure and history of co-morbidities at the diagnosis of epilepsy (model 
III).  Data are reported with odds ratios (OR) and 95% confidence intervals (CI).  All 
analyses were performed using SAS version 7.1 (SAS institute, Cary, NC, USA). 
3. Results 
There were 259 eligible adults with a new diagnosis of epilepsy, but 90 (35%) were 
excluded due to loss of follow-up or invalid sleep assessment at baseline and/or 12 
months.  Thus, 169 (65%) remained in the study group (median [interquartile range, 
IQR] age 42 [28-58] years, 55% male; Table e-1).  All participants self-completed the 
clinical and psychosocial assessments but with a nominated proxy present in 15 (9%) 
at baseline and 8 (5%) at 12 months.  Sixty-four percent of the study group had 
baseline interviews conducted beyond 28 days post-diagnosis (median [IQR] 48 [15-
113] days). 
Compared to those participants who were lost to follow-up or had incomplete or 




students (P=0.03), or experience economic hardship (P=0.003), and were more likely 
to be in paid work (P=0.05) and have an annual household income ≥Aust$100,400 
(P=0.02).  The study group were also more likely to have seizures during sleep or 
napping (P=0.03), and to have waited for ≥8 weeks for a specialist neurologist review 
(P=0.001).  Participants interviewed beyond 28 days, reported more perceived stigma 
(P=0.03) within the first month of diagnosis and more AED use (P=0.002), specifically 
levetiracetam (P=0.006), at the time of baseline interview, than those assessed earlier 
(Table e-2). 
3.1 Cross sectional association of insomnia symptoms and short sleep duration 
Insomnia symptoms was present in 33 participants (20%) at baseline, and 31 
participants (18%) at 12 months; while 39 participants (23%) at baseline and 38 
participants (22%) at 12 months reported a short sleep duration of ≤6 hours.  Insomnia 
symptoms at baseline was associated with treatment for mood disorders before 
seizures onset (P=0.04), co-morbidity (P=0.01) and use of levetiracetam (P=0.03), and 
a lower likelihood of seizures during naps (p=0.04), but no other demographic or 
clinical features.  Of the characteristics assessed only older participants (P=0.01) and 
those who owned accommodation (P=0.02) were more likely to report short sleep 
duration at baseline. 
3.2 Prospective pattern of insomnia symptoms and short sleep duration 
Fourteen participants (8%) with insomnia symptoms at baseline had recovered at 12 
months (recovery); 12 participants (7%) had new onset of insomnia symptoms at 12 
months (late); and 19 participants (11%) reported insomnia symptoms at both time 




17 (10%) and 21 (12%) were in late and chronic stages, respectively (Table 2 and 
Table e-3). 
3.3 Association of course of insomnia symptoms and short sleep duration and outcome 
There was no consistent association of the pattern of either insomnia symptoms or 
short sleep duration with the later presence of seizures or disability (Table 2).  There 
was a trend for those whose insomnia symptoms had recovered to be more likely to 
have ongoing seizures (adjusted odds ratio [aOR] 4.34, 95% CI 1.31 to 14.44), and 
those who had late onset insomnia symptoms to have greater disability (aOR 4.20, 95% 
CI 1.08 to 14.42), although these associations attenuated after adjustment for 
medication use.  Those with chronic short sleep duration were more likely to have 
ongoing seizures (aOR 3.58, 95% CI 1.16 to 10.99) after adjustment for age, sex and 
medication use, but this attenuated after adjustment for physical and psychological 
comorbidity. 
Chronic insomnia symptoms and short sleep were strongly associated with worse 
mental health (aOR 3.76, 95% CI 1.28 to 11.06; and aOR 5.41, 95% CI 1.86 to 15.79) 
and poorer quality of life at 12 months (aOR 3.02, 95% CI 1.03 to 8.84; and aOR 3.11, 
95% CI 1.10 to 8.82), after adjusting for clinical features of epilepsy and physical and 
psychological comorbidity.  New onset insomnia symptoms, but not new onset short 
sleep duration, showed a similar association. 
4. Discussion 
This prospective community-based study has shown that the problems of insomnia 
symptoms and short sleep duration are as common in people soon after a diagnosis 
of epilepsy as in the community, but no more so.  The frequency of insomnia symptoms 




difficulty getting to sleep or staying asleep in adult Australian surveys [26, 27], but was 
considerably lower than that reported in cross-sectional clinic-based studies of adults 
with established epilepsy (29% to 74%, the wide range of reported point prevalence 
being notable itself) [28].  Approximately one-fifth of our participants reported sleeping 
fewer than seven hours, which is much higher than that reported (5%) in the Australian 
population [29], but lower than that reported (34% [4] and 39% [1]) in adults with 
epilepsy in clinical studies.  These discrepancies might reflect the varying definitions 
and methods of assessing insomnia and short sleep duration, and in differences in the 
case-mix of study populations, e.g. our study group was newly diagnosed who are 
different to chronic clinical smaples.  For instance only a small proportion (n=12) of the 
sample required polytherapy, when polytherapy has been consistently associated with 
insomnia [3, 30]. 
People with generalized onset seizures were initally reported to have more frequent 
sleep abnormalities than those with focal seizures [13], but our data confirmed findings 
from a Greek study [2], that there was no association between focal or generalized 
seizure patterns with insomnia or short sleep duration.  In contrast to the previously 
reported association between nocturnal seizures and insomnia [31], our data showed 
an association between nocturnal seizures and the absence of insomnia symptoms. 
Half of this study group were not taking any anti-epileptic medication, which is 
consistent with the reported 37% of individuals with newly diagnosed epilepsy 
remained untreated up to 3 years after diagnosis [32].  There was no association of 
AED use with sleep disturbance over time (Table e-4), but levetiracetam, a second-
generation AED, was associated with insomnia symptoms at baseline in our study.  
Levetiracetam has been associated with subclinical depression,[33] and the overlap 




suggest fewer sleep problems than an older AED (carbamazepine) [11, 34], and 
improvement in both subjective parameters of sleep continuity and objective sleep 
efficiency (percentage of the time asleep/time in bed) in patients with epilepsy [35, 36], 
in a randomised trial participants with newly diagnosed epilepsy taking levetiracetam 
were 2.5 times more likely to report insomnia compared with their counterparts taking 
controlled-release carbamazepine, when used as the first treatment [37].  This may 
reflect confounding by indication as clinicians might be prescribing levetiracetam 
because of baseline sleep problems in this study, although there are opposite evidence.  
Insomnia ranked the 37th in decreasing order of adverse events frequency when 
levetiracetam (compared to placebo) was added onto usual AED care in treating drug-
resistant focal epilepsy [38], and was similarly uncommon among those with 
generalized seizures [39].  Further, when not used as an add-on treatment, 
levetiracetam was associated with lower odds of insomnia among veterans with 
epilepsy [40].  Valproic acid, often considered a “sedating” AED [40], was not 
associated with absence of insomnia symptoms in our study, although the numbers of 
patients on individual AEDs were small, and the assessement of AEDs is complicated 
by variable dose, duration, and interactions with other AEDs (although few participants 
required polytherapy). 
While there was no consistent association of the pattern of insomnia symptoms or short 
sleep duration with later seizure control or disability, chronic insomnia symptoms, short 
sleep, and new onset insomnia symptoms, were strongly associated with worse mental 
health and poorer quality of life at 12 months. Unlike commonly held clinical views we 
did not find any propsective association between insomnia symptoms or short sleep 
duration with later seizure control.  This may be due to the small sample size, as there 




those who had chronic short sleep duration, being more likely to have ongoing seizures 
(all P<0.1).  In adults with epilepsy, there are established cross-sectional associations 
between insomnia [2] or night awakenings [41] and more frequent seizures, and also 
for the occurrence of subjective daytime sleepiness and poor sleep quality in patients 
with drug-resistant temporal lobe epilepsy who later improve after a significant seizure 
reduction post-surgery [8].  In addition, there was no statistical association of patterns 
of insomnia symptoms or short sleep duration with WHODAS-measured global 
disability.  The relativley large OR for chronic insomnia symptoms and disability, was 
hampered by sample size, but is a similar effect size to that seen for the impact of 
chronic insomnia on disability post stroke[42]. 
Cross-sectional associations between insomnia and anxiety or depression have been 
recognized in epilepsy [3, 11, 30, 40, 43].  This is the first time this has been shown 
prospectively in epilepsy but insomnia consistently predicts future depression in 
gerneral population studies [44].  Cross-sectional and prospective associations 
between short sleep duration and depressive symptoms have been shown in an urban 
multi-ethnic cohort of older adults [45].  These associations were independent of 
previous diagnoses of depression but may still reflect a single underlying condition, 
which is supported by the stronger association with “late” insomnia symptoms.  
Conversely, chronic short sleep duration is more strongly associated with poor mental 
health than late short sleep duration, and thus is more likely to represent a risk factor. 
Consistent with the widely reported cross-sectional associations between insomnia [2, 
3, 43], or sleep quality [1, 3, 46] with quality of life in adults with epilepsy, our data have 
shown detrimental associations of insomnia symptoms or short sleep duration with EQ-
5D and VAS measures of quality of life.  There is additional cross-sectional evidence 




with short sleep duration, among older Chinese (≥60 years), after adjusting 
sociodemographic factors, health conditions and lifestyle habits [47].  We note that 
although an association between insomnia symptoms or short sleep duration and VAS 
measured quality of life existed, even after adjusting history of treatment for mood 
disorders before the first seizure, there may be mediating effects of later onset 
depression, between sleep quality or short sleep duration and self-reported life 
satisfaction [48]. 
Strengths of our study include the relatively large group of adults, recruited as early as 
possible after a diagnosis of epilepsy from multiple community and hospital locations 
in a defined population, and the focus on insomnia symptoms and short sleep duration 
as primary “exposure”, rather than general sleep complaints and quality without clear 
descriptions [1, 49], or a single item assessing poor sleep [41, 50].  We acknowledge, 
however, that attrition to the clinical cohort may have led to selection bias, while 
potential recall bias could have influenced the data among those participants who 
completed their baseline interviews more than 28 days after the diagnosis.  The 
“insomnia symptoms” were not adjudicated against standard measures as assessed 
by clinicians, and are only a proxy for Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) insomnia disorder 307.42 (F51.01)”.  Also, the term “chronic” used 
in this study should be differentiated from a “chronic insomnia” diagnosis.  We do not 
have information on sleep disturbance between two assessments, whereas the 
International Classification of Sleep Disorder (ICSD-3) duration criterion for chronic 
insomnia disorder is 3 months.  We acknowledge the lack of objective measurement 
of sleep duration, although the NSF`s recommendation does not rely on laboratory 
measured sleep time [20].  Furthermore, although Australians who experience 




health problems [51], our sample was too small to allow a reliable assessment of the 
co-existence of insomnia symptoms and short sleep duration, and even to allow in-
depth analyses of the impact of dynamic insomnia symptoms or short sleep duration 
courses on outcomes, especially when adjusted for confounders.  “Presence/absence 
of any seizure in the last past 8 month” cannot wholly represent the sophisticated 
seizure burden along with other crucial factors (e.g. seizure frequency, seizure type, 
and epilepsy syndromes) that may underpin the association.  Finally, we note the 
possibility for type I error due to multiple testing. 
In summary, our study has shown that one in five adults with a recent diagnosis of 
epilepsy have insomnia symptoms and/or short sleep duration, and in half, these 
become chronic problems over the subsequent 12 months.  Being statistically under-
powered may have precluded detection of a relation between habitual sleep 
disturbance and presence of going seizures or disability.  However, there was a strong 
association between insomnia symptoms and short sleep duration and psychological 
wellbeing. Importantly, although there were cross sectional associations of insomnia 
symptoms and short sleep duration with poor mental health and quality of life, those 
whose sleep improved also demonstrated no long term adverse psychosocial sequelae, 
providing a strong rationale for testing the effectiveness of sleep interventions in people 
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Table 1  Association of insomnia symptoms and short sleep duration in the first month after the diagnosis of epilepsy with baseline 
participant characteristics 
Variables at baseline (i.e. within 28 days after 
the diagnosis of epilepsy), unless specified 




Short sleep duration 
P value 
Yes (n = 33) No (n = 136) Yes (n = 39) No (n = 130) 
Demographic and socioeconomic        
Age, years, median (IQR), n 42 (28, 58), 169 48 (33, 64), 33 40 (27, 57), 136 0.13 48 (35, 65), 39 38 (26, 56), 130 0.01 
Male 93 (55) 16 (48) 77 (57) 0.40 24 (62) 69 (53) 0.35 
Married/partnereda 92/164 (56) 16/32 (50) 76/132 (58) 0.44 22 (56) 70/125 (56) 0.96 
Live alone 25/167 (15) 7/32 (22) 18/135 (13) 0.22 7/38 (18) 18/129 (14) 0.50 
Post-secondary educationb 82 (49) 15 (45) 67 (49) 0.69 16 (41) 66 (51) 0.29 
Current full/part time student 28/164 (17) 3/32 (9) 25/132 (19) 0.20 3 (8) 25/125 (20) 0.07 
Employedc before the first seizure 117/155 (75) 20/30 (67) 97/125 (78) 0.21 25/37 (68) 92/118 (78) 0.20 
Main income earner 80/149 (54) 14/28 (50) 66/121 (55) 0.66 21/34 (62) 59/115 (51) 0.28 
Annual household income ≥Aust$100,400 76/161 (47) 11/31 (35) 65/130 (50) 0.15 13/38 (34) 63/123 (51) 0.07 
Economic hardshipd before the diagnosis 46/167 (28) 11 (33) 35/134 (26) 0.41 11 (28) 35/128 (27) 0.92 
Private health insurance 99 (59) 21 (64) 78 (57) 0.51 20 (51) 79 (61) 0.29 
Own accommodation with/without mortgagee 85 (50) 20 (61) 65 (48) 0.19 26 (67) 59 (45) 0.02 
≥2 preschool or school aged children in the 
household 
25/148 (17) 3/26 (12) 22/122 (18) 0.42 4/32 (13) 21/116 (18) 0.45 
Psychosocial        
Family function (APGAR), median (IQR), n 15 (13, 15), 165 15 (13, 15), 32 15 (13, 15), 133 0.88 15 (14, 15), 39 15 (13, 15), 126 0.45 
Risky drinking level (≥5 for men, ≥4 for women 
on WHO-AUDIT) 
47 (28) 6 (18) 41 (30) 0.17 8 (21) 39 (30) 0.25 
Job strainf in the month before the first seizure 25/115 (22) 2/19 (11) 23/96 (24) 0.19 6/24 (25) 19/91 (21) 0.66 
Treatment for mood disordersg before the first 
seizure 
30/166 (18) 10/33 (30) 20/133 (15) 0.04 10/39 (26) 20/127 (16) 0.16 
Anxiety or depression (≥8 on HADS 
anxiety/depression subscales) 
52/162 (32) 14/32 (44) 38/130 (29) 0.12 17/38 (45) 35/124 (28) 0.06 
Disability (WHODAS), median (IQR), n 2 (1, 6), 168 3 (1, 8), 33 2 (1, 5), 135 0.12 2 (1, 6), 39 2 (1, 5), 129 0.56 
Perceived stigmah 41/167 (25) 9 (27) 32/134 (24) 0.69 9 (23) 32/128 (25) 0.81 
Clinical        
Co-morbidityi 61 (36) 18/33 (55) 43/136 (32) 0.01 19 (49) 42/130 (32) 0.06 
Symptomaticj 63 (37) 13 (39) 50 (37) 0.78 17 (44) 46 (35) 0.35 
Generalised onsetk 48/97 (49) 10/21 (48) 38/76 (50) 0.85 11/26 (42) 37/71 (52) 0.39 
Seizure during sleep/nap 63/154 (41) 8/32 (25) 55/122 (45) 0.04 14/34 (41) 49/120 (41) 0.97 
Seizures within 2 hours after sleep/nap 21/155 (14) 3/32 (9) 18/123 (15) 0.44 4/36 (11) 17/119 (14) 0.63 




Variables at baseline (i.e. within 28 days after 
the diagnosis of epilepsy), unless specified 




Short sleep duration 
P value 
Yes (n = 33) No (n = 136) Yes (n = 39) No (n = 130) 
≥8 weeks for neurologist review 37/164 (23) 7/32 (22) 30/132 (23) 0.92 6/37 (16) 31/127 (24) 0.29 
At the time of baseline assessment for the 
following 
       
Taking any anti-epileptic medication 83/167 (50) 18/32 (56) 65/135 (48) 0.41 20/38 (53) 63/129 (49) 0.68 
Good adherence (taking medication regularly) 72/81 (89) 17/18 (94) 55/63 (87) 0.40 17/19 (89) 55/62 (89) 0.93 
Carbamazepine 24/167 (14) 3/32 (9) 21/135 (16) 0.37 5/38 (13) 19/129 (15) 0.81 
Levetiracetam 22/167 (13) 8/32 (25) 14/135 (10) 0.03 8/38 (21) 14/129 (11) 0.10 
Valproic acid 29/167 (17) 7/32 (22) 22/135 (16) 0.45 6/38 (16) 23/129 (18) 0.77 
Data are number of participants (percentage), or median (interquartile range, [IQR]) and number of participants.  If there were missing values, the actual denominators were presented.  P values are 
for the comparisons of participants with versus without insomnia symptoms and participants with versus without short sleep duration, and are in bold font when <0.05.  Kruskal-Wallis and Chi squared 
tests were used for continuous and categorical variables, respectively. 
Family APGAR denotes Family Adaptation, Partnership, Growth, Affection and Resolve questionnaire; WHO-AUDIT, World Health Organization`s Alcohol Use Disorders Identification Test, alcohol 
consumption part; HADS, Hospital Anxiety and Depression Scale; WHODAS, World Health Organization`s Disability Assessment Schedule. 
aVersus no current partner (i.e. never married, widowed, divorced or separated) 
bVersus no formal schooling, completed primary or secondary school 
cFull/part time paid employment versus retired or do not have a paid job 
dExperiencing economic hardship was define as either an instance of a household`s inability to make a necessary household payment (i.e. gas, electricity or telephone bills, heat or cool home, 
mortgage or rent payments, etc.) or the demonstration of dissaving behavior (i.e. borrowing or use of savings, sell assets, borrow money, etc.) 
eVersus rented, boarding house/hostel or other 
fMeasured by the Job Content Questionnaire. Job strain was defined as high demands and low control 
gUse of antidepressants, sleeping tablets, medication for anxiety/anxiolytics/benzodiazepine, major tranquilizers and psychotherapy 
hAs a result of epilepsy, the participants think that other people are uncomfortable, treat them differently, or prefer to avoid them 
iIncludes self-reported cardiovascular, respiratory, ophthalmology, otorhinolaryngology, gastrointestinal, hepatic, renal, genito-urinary, musculoskeletal and endocrine-metabolic diseases, but not 
including neurological (e.g. epilepsy) and psychiatric/behavioral conditions 
jSymptomatic epilepsy due to encephalitis or meningitis, head injury, stroke or brain operation, versus idiopathic epilepsy 





Table 2  Association of insomnia symptoms and short sleep duration course with 12-month outcomes 




Model I Model II Model III 
Pattern of short sleep 
duration Model I Model II Model III 
Outcome 1: any seizure in the past 8 months (55 cases) 
Never (n = 124)  Never (n = 113)  
Chronic (n = 19) 1.42 (0.49 to 4.08) 1.29 (0.43 to 3.88) 0.78 (0.23 to 2.59) Chronic (n = 21) 2.76 (0.99 to 7.71) 3.58 (1.16 to 10.99)a 2.81 (0.85 to 9.28) 
Recovery (n = 14) 4.34 (1.31 to 14.44)a 3.26 (0.97 to 10.97) 3.08 (0.85 to 11.20) Recovery (n = 18) 1.35 (0.44 to 4.11) 1.29 (0.39 to 4.30) 1.22 (0.34 to 4.40) 
Late (n = 12) 2.95 (0.85 to 10.29) 2.87 (0.77 to 10.66) 2.18 (0.56 to 8.51) Late (n = 17) 2.47 (0.83 to 7.37) 2.26 (0.73 to 6.99) 2.33 (0.73 to 7.38) 
Outcome 2: anxiety or depression (40 cases)1 
Never (n = 124)  Never (n = 113)  
Chronic (n = 19) 3.92 (1.37 to 11.23)a 3.76 (1.28 to 11.06)a  Chronic (n = 21) 5.86 (2.09 to 16.37)c 5.41 (1.86 to 15.79)b  
Recovery (n= 14) 1.37 (0.35 to 5.41) 1.03 (0.25 to 4.24)  Recovery (n = 18) 1.39 (0.41 to 4.75) 1.54 (0.44 to 5.45)  
Late (n = 12) 9.87 (2.72 to 35.86)c 8.59 (2.30 to 32.12)b  Late (n = 17) 1.97 (0.62 to 6.26) 1.68 (0.51 to 5.49)  
Outcome 3: greater disability at 12 months (78 cases) 
Never (n = 124)  Never (n = 113)  
Chronic (n = 19) 1.76 (0.65 to 4.73) 1.65 (0.56 to 4.80) 1.30 (0.42 to 4.08) Chronic (n = 21) 1.84 (0.70 to 4.84) 1.70 (0.58 to 4.98) 1.57 (0.51 to 4.86) 
Recovery (n= 14) 0.95 (0.31 to 2.94) 0.51 (0.15 to 1.73) 0.48 (0.14 to 1.74) Recovery (n = 18) 1.62 (0.59 to 4.48) 1.46 (0.48 to 4.44) 1.52 (0.50 to 4.68) 
Late (n = 12) 4.20 (1.08 to 14.42)a 3.62 (0.84 to 15.60) 3.11 (0.74 to 13.19) Late (n = 17) 1.55 (0.55 to 4.36) 1.19 (0.41 to 3.47) 1.28 (0.42 to 3.86) 
Outcome 4a: worse quality of life on EQ-5D (64 cases) 
Never (n = 124)    Never (n = 113)    
Chronic (n = 19) 1.88 (0.68 to 5.22) 1.70 (0.56 to 5.15) 1.31 (0.41 to 4.22) Chronic (n = 21) 1.79 (0.67 to 4.78) 1.60 (0.54 to 4.72) 1.30 (0.42 to 4.07) 
Recovery (n= 14) 1.67 (0.53 to 5.23) 0.97 (0.29 to 3.24) 0.94 (0.27 to 3.28) Recovery (n = 18) 1.22 (0.42 to 3.52) 1.28 (0.40 to 4.10) 1.20 (0.37 to 3.89) 
Late (n = 12) 1.96 (0.59 to 6.58) 1.42 (0.38 to 5.27) 1.13 (0.29 to 4.42) Late (n = 17) 7.68 (2.28 to 25.85)c 6.50 (1.88 to 22.45)b 6.87 (1.94 to 24.32)b 
Outcome 4b: worse global rating of quality of life (67 cases) 
Never (n = 124)  Never (n = 113)  
Chronic (n = 19) 3.55 (1.28 to 9.88)a 3.38 (1.19 to 9.56)a 3.02 (1.03 to 8.84)a Chronic (n = 21) 3.11 (1.16 to 8.31)a 3.11 (1.13 to 8.59)a 3.11 (1.10 to 8.82)a 
Recovery (n = 14) 0.51 (0.13 to 1.94) 0.39 (0.10 to 1.53) 0.40 (0.10 to 1.63) Recovery (n = 18) 1.30 (0.46 to 3.67) 1.41 (0.48 to 4.13) 1.44 (0.49 to 4.26) 
Late (n = 12) 5.75 (1.46 to 22.59)a 5.07 (1.26 to 20.43)a 4.65 (1.15 to 18.74)a Late (n = 17) 2.25 (0.80 to 6.33) 2.02 (0.71 to 5.76) 2.11 (0.73 to 6.12) 
EQ-5D denotes EuroQol Group 5-Dimension self-reported questionnaire 
1To avoid overfitting of model, the minimum number of outcome events per independent variable entered into the logistic regression model is 10.  Fourty cases 
of anxiety of depression do not allow for Model III, where six variables need to be adjusted. 
Model I is adjusted for age and sex.  Model II sequentially adjusted for on/off antiepileptic medication at 12 months assessment, and presence/absence of 
ongoing seizures in the past 8 months at 12 months assessment (not applicable for outcome 1).  Model III sequentially adjusted for history of treatment for mood 
disorder before the first seizure and history of co-morbidities at the diagnosis of epilepsy. 
aP<0.05; bP<0.01; cP<0.001 
 
 
